Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,485.25GBp
1:49pm BST
Change (% chg)

5.25 (+0.35%)
Prev Close
1,480.00
Open
1,482.00
Day's High
1,489.00
Day's Low
1,472.50
Volume
2,988,065
Avg. Vol
8,741,724
52-wk High
1,745.56
52-wk Low
1,444.00

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.21
Market Cap(Mil.): £72,935.55
Shares Outstanding(Mil.): 4,918.52
Dividend: 19.00
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.47 15.77
EPS (TTM): -- -- --
ROI: -- 14.26 15.19
ROE: -- 15.57 13.80

FDA declines to approve J&J arthritis drug sirukumab

The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.

25 Sep 2017

CORRECTED-UPDATE 2-FDA declines to approve J&J arthritis drug sirukumab

Sept 22 The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.

25 Sep 2017

BRIEF-Theravance Biopharma highlights positive results from impact study of Trelegy Ellipta

* Theravance Biopharma highlights positive headline results from impact study of Trelegy Ellipta announced by Glaxosmithkline and Innoviva

20 Sep 2017

BRIEF-GlaxoSmithkline and Innoviva announces positive impact results for Trelegy in COPD

* CO, INNOVIVA REPORT POSITIVE HEADLINE RESULTS FROM STUDY SHOWING SINGLE INHALER TRIPLE THERAPY TRELEGY ELLIPTA REDUCED COPD EXACERBATIONS

20 Sep 2017

GlaxoSmithKline breathes easier as U.S. approves triple lung drug

LONDON U.S. regulators have approved GlaxoSmithKline's three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair.

19 Sep 2017

UPDATE 1-GlaxoSmithKline breathes easier as U.S. approves triple lung drug

* CEO sees it as one of three "critical" new drug launches (Adds detail on competition, analyst reaction, shares)

19 Sep 2017

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

19 Sep 2017

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

19 Sep 2017

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

Sept 18 GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

19 Sep 2017

Gates Foundation invests $40 million in UK immunotherapy company

LONDON The Bill & Melinda Gates Foundation is to invest up to $40 million (29.41 million pounds) in privately held British biotech company Immunocore to support its development of immunotherapies for infectious diseases.

18 Sep 2017

Earnings vs. Estimates